DK1250152T3 - Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer - Google Patents

Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer

Info

Publication number: DK1250152T3
Authority: DK; Denmark
Prior art keywords: cancer; treatment; composition containing; hyaluronic acid; synergistic composition
Prior art date: 1999-12-28

Application number

DK00986939.7T

Other languages

English (en)

Inventor

Nigel C Phillips

Mario C Filion

Original Assignee

Bioniche Urology Ip Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-28

Filing date

2000-12-28

Publication date

2013-08-26

2000-12-28 Application filed by Bioniche Urology Ip Inc filed Critical Bioniche Urology Ip Inc

2013-08-26 Application granted granted Critical

2013-08-26 Publication of DK1250152T3 publication Critical patent/DK1250152T3/da

Links

KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
229920002674 hyaluronan Polymers 0.000 title 1
229960003160 hyaluronic acid Drugs 0.000 title 1
230000002195 synergetic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Mycology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

DK00986939.7T 1999-12-28 2000-12-28 Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer DK1250152T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17337599P	1999-12-28	1999-12-28
PCT/CA2000/001562 WO2001047561A1 (en)	1999-12-28	2000-12-28	Hyaluronic acid in the treatment of cancer

Publications (1)

Publication Number	Publication Date
DK1250152T3 true DK1250152T3 (da)	2013-08-26

Family

ID=22631719

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK00986939.7T DK1250152T3 (da)	1999-12-28	2000-12-28	Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer

Country Status (8)

Country	Link
US (1)	US7125858B2 (da)
EP (1)	EP1250152B1 (da)
JP (1)	JP4215429B2 (da)
AU (1)	AU784356B2 (da)
CA (1)	CA2395493C (da)
DK (1)	DK1250152T3 (da)
NZ (1)	NZ520312A (da)
WO (1)	WO2001047561A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1140198T3 (da)	1999-01-13	2008-03-10	Alchemia Oncology Pty Ltd	Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
US20020091095A1 (en) *	1999-12-13	2002-07-11	Phillips Nigel C.	Modulation of Fas and FasL expression
AU785212B2 (en) *	1999-12-13	2006-11-09	Bioniche Life Sciences Inc.	Therapeutically useful synthetic oligonucleotides
US9066919B2 (en)	2000-07-14	2015-06-30	Alchemia Oncology Pty Limited	Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) *	2000-07-14	2000-08-10	Meditech Research Limited	Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US8039602B2 (en)	2000-10-31	2011-10-18	Ryogen Llc	Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
US7087586B2 (en) *	2001-04-24	2006-08-08	Bioniche Life Sciences, Inc.	Oligonucleotide compositions and their use to induce differentiation of cells
ITPD20020271A1 (it)	2002-10-18	2004-04-19	Fidia Farmaceutici	Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
JP4851185B2 (ja)	2003-05-16	2012-01-11	ジェレックスインターナショナル株式会社	アレルギー症状抑制剤及び空気濾過フィルター
US20060240084A1 (en) *	2005-04-20	2006-10-26	Xylos Corporation	Microbial cellulose materials for use in transdermal drug delivery systems, method of manufacture and use
JP5465431B2 (ja) *	2005-07-27	2014-04-09	アルケミアオンコロジーピーティーワイリミテッド	ヒアルロナンを用いる治療プロトコル
WO2007028196A1 (en) *	2005-09-07	2007-03-15	Alchemia Oncology Pty Limited	Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
WO2008070538A2 (en) *	2006-12-01	2008-06-12	Anterios, Inc.	Micellar nanoparticles comprising botulinum toxin
DE102009035586A1 (de)	2009-07-31	2011-02-03	Fresenius Kabi Deutschland Gmbh	Intravesikale Instillationslösungen zur Behandlung von Blasenkrebs
DK2480669T3 (da)	2009-09-25	2018-02-12	Curna Inc	Behandling af filaggrin- (flg) relaterede sygdomme ved modulering af flg-ekspression og -aktivitet
BR112013008727A2 (pt)	2010-10-13	2016-06-28	Bioniche Urology Ip Inc	composições de parede celular de ácido ribonucleico micobacteriano e métodos de fabricação e uso das mesmas
US20160175457A1 (en) *	2013-09-12	2016-06-23	Dsm Ip Assets B.V.	Ocular device
AU2017360346B2 (en)	2016-11-21	2023-11-23	Eirion Therapeutics, Inc.	Transdermal delivery of large agents
ES2947713T3 (es)	2019-06-13	2023-08-17	Hollister Inc	Productos de catéter urinario reutilizables
WO2020263859A1 (en)	2019-06-25	2020-12-30	Hollister Incorporated	Reusable urinary catheter products
US20210000910A1 (en)	2019-07-03	2021-01-07	Jysk Skin Solutions Pte Ltd	Topical compositions
JP7500038B2 (ja) *	2019-08-27	2024-06-17	国立研究開発法人物質・材料研究機構	炎症性サイトカイン産生抑制材、ヒアルロン酸誘導体、及び、ヒアルロン酸誘導体の製造方法。
JP2023534295A (ja) *	2020-07-17	2023-08-08	ジェロン・コーポレーション	皮下テロメラーゼ阻害剤組成物及びそれらを使用するための方法
US12083204B2 (en)	2022-06-02	2024-09-10	L'oreal	Topical composition for homeostatic delivery of nitric oxide and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3172815A (en)	1962-04-24	1965-03-09	Warner Lambert Pharmaceutical	Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
FR2160326B1 (da)	1971-11-19	1975-02-07	Anvar
US4152423A (en)	1971-11-19	1979-05-01	Agence Nationale De Valorisation De La Recherche (Anvar)	Immunological agents
CH602920A5 (da)	1973-02-23	1978-08-15	Wellcome Found
US3976544A (en)	1973-06-19	1976-08-24	The Agence Nationale De Valorisation De Le Recherche	Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr)	1976-06-04	1978-07-13	Merieux Inst	Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en)	1978-03-10	1979-11-01	Mitsui Toatsu Chem Inc	Anti-tumor substance and its preparation
DE3011461C2 (de)	1980-03-25	1986-10-30	Dr. Madaus & Co, 5000 Köln	Verwendung von Propionibakterien
US4520019A (en)	1982-04-29	1985-05-28	Ribi Immunochem Research, Inc.	Stable composition and preparation thereof
US4579941A (en)	1982-08-13	1986-04-01	Mitsuitoatsu Chemicals, Inc.	Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en)	1983-09-23	1987-05-05	Ribi Immunochem Research, Inc.	Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en)	1984-02-17	1984-03-21	Stanford J L	Biological preparations
DE3408768A1 (de)	1984-03-09	1985-09-12	Bayer Ag, 5090 Leverkusen	Immunstimulierende mittel
US4744984A (en)	1985-10-08	1988-05-17	Vetrepharm Research, Inc.	Antiviral immunotherapeutic agent and preparation thereof
WO1987002679A1 (en)	1985-10-31	1987-05-07	The Australian National University	Immunotherapeutic treatment
US4877611A (en)	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
US4837202A (en)	1987-09-14	1989-06-06	Pitman-Moore, Inc.	Method for stimulating the immune system
DE3818054C2 (de)	1988-05-27	1994-02-17	Biotest Pharma Gmbh	Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
CA1340994C (en) *	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Treatment of conditions and disease
CA2122519C (en)	1994-04-29	2001-02-20	Rudolf Edgar Dr. Falk	Cancer treatment and metastasis prevention
WO1998017320A1 (en)	1991-07-03	1998-04-30	Hyal Pharmaceutical Corporation	Use of hyaluronan in gene therapy
WO1994016727A1 (en)	1993-01-29	1994-08-04	Vetrepharm, Inc.	Immunotherapeutic composition
AU6362594A (en) *	1993-03-10	1994-09-26	Miles Inc.	Hyaluronic acid used as a cancer treatment
IN181358B (da)	1995-02-14	1998-05-30	Bioniche Inc
WO1997033612A1 (en)	1996-03-15	1997-09-18	Immunotherapy, Inc.	Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-link treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
CA2208924A1 (en)	1997-07-09	1999-01-09	Hyal Pharmaceutical Corporation	Sparing paclitaxel by the use of hyaluronan
JP4335435B2 (ja)	1997-08-05	2009-09-30	バイオニケライフサイエンシーズインコーポレイテッド	細胞増殖および細胞死を調節する組成物および方法
DE69829316T2 (de)	1998-02-18	2006-04-13	Bioniche Life Sciences Inc., Belleville	Behandlung des harnblasenkrebses durch mycobacterium phlei zellwand
CA2353905C (en)	1998-12-04	2010-06-22	Nigel C. Phillips	Chemotherapeutic composition and method
DK1140198T3 (da)	1999-01-13	2008-03-10	Alchemia Oncology Pty Ltd	Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
CA2266188A1 (en)	1999-03-19	2000-09-19	Stephen Chizick	Natural preparation for treatment of male pattern hair loss

2000
- 2000-12-28 WO PCT/CA2000/001562 patent/WO2001047561A1/en not_active Ceased
- 2000-12-28 EP EP00986939.7A patent/EP1250152B1/en not_active Expired - Lifetime
- 2000-12-28 CA CA2395493A patent/CA2395493C/en not_active Expired - Fee Related
- 2000-12-28 AU AU23364/01A patent/AU784356B2/en not_active Ceased
- 2000-12-28 DK DK00986939.7T patent/DK1250152T3/da active
- 2000-12-28 US US10/168,327 patent/US7125858B2/en not_active Expired - Fee Related
- 2000-12-28 NZ NZ520312A patent/NZ520312A/en not_active IP Right Cessation
- 2000-12-28 JP JP2001548149A patent/JP4215429B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP4215429B2 (ja)	2009-01-28
CA2395493A1 (en)	2001-07-05
CA2395493C (en)	2010-06-22
JP2003518510A (ja)	2003-06-10
US7125858B2 (en)	2006-10-24
AU2336401A (en)	2001-07-09
EP1250152A1 (en)	2002-10-23
AU784356B2 (en)	2006-03-16
US20030176381A1 (en)	2003-09-18
NZ520312A (en)	2003-08-29
WO2001047561A1 (en)	2001-07-05
EP1250152B1 (en)	2013-05-15

Publication	Publication Date	Title
DK1250152T3 (da)	2013-08-26	Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer
DK2412368T3 (da)	2013-11-04	Sammensætning til behandling af ar
DE60014873D1 (de)	2004-11-18	Synergistische zusammensetzungen zur krebsbehandlung
DK1196163T3 (da)	2010-03-29	Farmaceutiske sammensætninger til behandling af insulinresistens
PL351134A1 (en)	2003-03-24	Compositions for treatment of disorders of the oesophagus
DK1147083T3 (da)	2004-08-16	Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1173059T3 (da)	2006-02-20	Fremgangsmåde til forögelse af biologisk virkningsfuldhed af plantebehandlingssammensætninger
IT1318649B1 (it)	2003-08-27	Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
DE60019556D1 (de)	2005-05-25	2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
NO20006630D0 (no)	2000-12-22	Farmasöytisk sammensetning for behandlingen av diabetes
DK1384478T3 (da)	2011-05-23	Antibiotiske sammensætninger indeholdende moxifloxacin til behandling af øjet
DK1259512T3 (da)	2003-12-29	Pteridinforbindelser til behandling af psoreasis
DE10082139T1 (de)	2001-10-04	Zusammensetzung zur Behandlung von Reibungspaaren
DK1450606T3 (da)	2011-05-23	Synergistiske sammensætninger til behandling af såsæd
DK1156806T3 (da)	2004-08-02	Farmaceutisk sammensætning indeholdende protonpumpeinhibitor
DK1176964T3 (da)	2007-01-15	Brug af ET743 til behandling af cancer
DK1150991T3 (da)	2004-06-07	Præparater til behandling af inflammatoriske reaktioner
HUP0402341A3 (en)	2005-11-28	Compositions containing thiazol-2-ylamines for the treatment of cancer
DK1150681T3 (da)	2006-05-22	Anvendelse af en farmaceutisk sammensætning indeholdende desoxypeganin til behandling af nikotinafhængighed
PT1227817E (pt)	2004-11-30	Composicao farmaceutica aquosa contendo ciclesonida
IL133760A0 (en)	2001-04-30	Composition for the treatment of dandruff
PT1165031E (pt)	2005-09-30	Composicao do resorcinol
NO20022000D0 (no)	2002-04-26	6-metoksy-2-naftyleddiksyre-prodrogesammensetninger til behandling av inflammasjon
DK1224181T3 (da)	2004-04-13	Substituerede pyrroler som antiproliferative midler til behandling af cancer
DE60015133D1 (de)	2004-11-25	Synergistische zusammensetzung von bioziden